A Bioengineer.org report frames colorimetry as the missing numeric yardstick for post-inflammatory hyperpigmentation (PIH). The framing centers on imaging-based color measurement replacing the visual scales that have scored PIH in clinic and trial settings.

Why does PIH need a numeric score?

Post-inflammatory hyperpigmentation is the brown, tan, or slate-gray stain that lingers after acne, eczema, psoriasis flares, burns, laser treatments, and cosmetic procedures. It lands hardest on patients with Fitzpatrick III-VI skin, where melanin-rich skin responds to inflammation with excess pigment deposition. PIH disproportionately affects patients of African, South Asian, and Latin American descent, and individual lesions can persist for months to years without intervention.

Most clinicians grade PIH with ordinal scales — clinician global impression, the Pigmentary Change Index, and similar visual references. The scales ask a trained eye to match a lesion to a reference panel, and inter-rater agreement drifts across skin types and lighting conditions. Sponsors running acne, melasma, and post-procedure studies have flagged the inconsistency as a barrier to clean regulatory packages, and agency reviewers have asked sponsors to bring quantitative endpoints to pivotal trials.

What does colorimetry actually measure?

Colorimeters — handheld probes that shine controlled light on skin and read the reflected spectrum — convert color into numeric values. Two systems dominate dermatology research: the CIE Lab* color space, which yields a lightness number (L*), a red-green number (a*), and a blue-yellow number (b*); and the melanin index, which distills the spectrum into a single pigment reading. Devices ship from vendors including Courage+Khazaka, Delfin Technologies, and a handful of imaging-platform makers.

Readings reproduce across operators, machines, and time points. The same probe on the same lesion a week apart delivers a delta, not a feel. Continuous numeric endpoints let sponsors tighten effect sizes against placebo and shrink per-arm enrollment, two pressures that have nudged pigment trials toward objective instruments for years.

What changes if PIH gets an objective readout?

Three workflows feel it first.

• Clinical trials — Sponsors running acne, melasma, and post-inflammatory studies could substitute melanin-index reduction for visual scores, mirroring how EASI anchors atopic dermatitis readouts and how PGA anchors psoriasis trials. FDA and EMA reviewers have signaled appetite for continuous, device-derived endpoints in pigment indications.
• Patient counseling — A patient watches a melanin-index number drop from the high 300s to the low 200s and reads progress without leaning on a clinician's grade. Devices from Courage+Khazaka and similar vendors already sit in research clinics; they head next to routine acne and aesthetic workflows.
• Equity — Standardized readings cut the bias baked into visual scales historically validated on lighter skin, where clinicians see pigment contrast more easily but the clinical stakes often differ. A melanin-index probe does not see the patient's ethnicity; it reads reflected light the same way every visit.

What's the next readout?

Bioengineer.org's headline coverage did not break out trial endpoints, device specifics, or investigator names in the version Derm Field reviewed. The direction, though, is familiar: where EASI standardized eczema and PASI standardized psoriasis, pigment disorders still lack an analogous ruler. Watch the next wave of acne and melasma readouts for pigment-measurement endpoints — colorimetry, given its low hardware cost and long research footprint, sits as the most-deployed candidate to fill that role.